RecruitingNCT07451002
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
An OBServational Prospective Study in France: Adherence to APAlutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in France
Sponsor
Janssen Cilag S.A.S.
Enrollment
270 participants
Start Date
Dec 18, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria7
- Male (based on chromosomal composition at birth) and aged greater than or equal to (\>=) 18 years.
- Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
- Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
- Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy \[ADT\]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
- Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
- Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
- Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide
Exclusion Criteria9
- Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
- Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
- Is currently receiving active treatment for prostate cancer as part of an interventional study
- Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
- Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
- Beneficiary of State Medical Aid \[AME\]
- Does not speak/read French
- Under guardianship or curatorship
- Under judicial protection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07451002
Related Trials
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT0605683027 locations
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT073198713 locations
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT056166501 location
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT070829206 locations
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737274 locations